Combining Aurora Kinase Inhibitors with Paclitaxel in Ovarian Cancer
Author Information
Author(s): Christopher D Scharer, Noelani Laycock, Adeboye O Osunkoya, Sanjay Logani, John F McDonald, Benedict B Benigno, Carlos S Moreno
Primary Institution: Emory University School of Medicine
Hypothesis
Can the chemical inhibition of the Aurora kinase family using VE-465 synergize with paclitaxel to induce apoptosis in ovarian cancer cells?
Conclusion
VE-465 is a potent inducer of apoptosis in taxane-resistant ovarian cancer cells and can enhance the effects of paclitaxel at low doses.
Supporting Evidence
- VE-465 induced a 4.5-fold increase in apoptosis in paclitaxel-sensitive 1A9 cells compared to paclitaxel alone.
- VE-465 was effective at inducing apoptosis in both taxol-sensitive and taxol-resistant ovarian cancer cell lines.
- High levels of Aurora-A expression in tumors may indicate a potential benefit from combination therapy.
Takeaway
This study found that a drug called VE-465 can help kill ovarian cancer cells, especially when used with another drug called paclitaxel.
Methodology
The study used expression profiling, drug treatment, flow cytometry, and caspase assays to evaluate the effects of VE-465 and paclitaxel on ovarian cancer cells.
Potential Biases
Potential bias due to the use of specific cell lines and the focus on a limited number of genes.
Limitations
The study had a small sample size and focused on specific cell lines, which may not represent all ovarian cancer cases.
Participant Demographics
The study involved ovarian cancer patients with varying stages and treatment histories.
Statistical Information
P-Value
p<0.0025
Statistical Significance
p<0.0025
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website